Wellthy Therapeutics, a diabetes management startup, has recently raised $4mn in a pre-Series A funding round from early-stage VC firm Saamna Capital.
The recent funding in the startup comes after a two year gap when the company had raised seed funding from Ranjan Pai’s family office MEMG, according to an Entrackr report. In 2018, the company had raised $2.1 million in seed funding from MEMG while pharma giant Cipla had picked up 11.71% stake for Rs 10.5 crore in February last year.
As per the company filings, Wellthy has allotted 9,39,983 pre-Series A compulsorily convertible preference shares (CCPS) and 10 equity shares to Saama Capital at a price of Rs 322.673 per share to raise the investment.
Wellthy was founded in 2015 by Abhishek Shah, Prayat Shah, and Aradh Pillai. The company primarily focuses on type 2 diabetes care through a mobile app that lets users log their meals and monitor their blood sugar levels over time.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.